Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Alpha Tau Medical Ltd specializes in innovative cancer treatment through its proprietary Alpha DaRT technology, which targets tumors with alpha radiation while minimizing damage to surrounding healthy tissue. The company is positioned in the oncology sector, primarily focusing on markets in the United States and Europe, where it aims to address significant unmet medical needs in cancer therapy.
Alpha Tau Medical generates revenue through the sale of its Alpha DaRT technology, which is a unique cancer treatment method that offers a competitive advantage due to its targeted approach and reduced side effects compared to traditional therapies. The company leverages partnerships with hospitals and cancer treatment centers to expand its market reach and establish pricing power.
Regulatory approvals for new treatment indications for Alpha DaRT
Clinical trial results demonstrating efficacy and safety
Partnership announcements with healthcare providers or pharmaceutical companies
Market adoption rates in key geographies like the US and EU
Regulatory changes impacting approval processes for medical devices
Technological disruption from competing cancer therapies
Emergence of alternative cancer treatments with similar efficacy
Pricing pressure from established oncology companies
Negative cash flow impacting operational sustainability
High reliance on equity financing to fund operations
low - the demand for cancer treatment is relatively inelastic, as patients require care regardless of economic conditions.
Moderate - higher interest rates could increase the cost of capital for funding clinical trials and operational expenses, potentially impacting growth.
minimal - the company has a low debt-to-equity ratio, indicating limited reliance on credit.
growth - investors looking for high-risk, high-reward opportunities in the biotech sector.
high - the stock has exhibited significant price volatility, reflecting the uncertainties inherent in clinical development.
